TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04732507

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: 1% plain lidocaine and 0.25% plain bupivacaine
Description: A 5- or 10-ml syringe will be filled equally with 1% plain lidocaine and 0.25% plain bupivacaine. A 1.5-inch 25-gauge needle will be attached to the syringe. The needle will be carefully inserted at the first trigger point and 2 mls of the mixed local anesthetic will be infiltrated. At that point, the needle will be carefully inserted into the trigger point based on the group assigned. Once needling is done for the first trigger point, the process will be repeated in exactly the same fashion for the remaining points.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: 1% plain lidocaine and 0.25% plain bupivacaine
Description: A 5- or 10-ml syringe will be filled equally with 1% plain lidocaine and 0.25% plain bupivacaine. A 1.5-inch 25-gauge needle will be attached to the syringe. The needle will be carefully inserted at the first trigger point and 2 mls of the mixed local anesthetic will be infiltrated. At that point, the needle will be carefully inserted into the trigger point based on the group assigned. Once needling is done for the first trigger point, the process will be repeated in exactly the same fashion for the remaining points.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: 1% plain lidocaine and 0.25% plain bupivacaine
Description: A 5- or 10-ml syringe will be filled equally with 1% plain lidocaine and 0.25% plain bupivacaine. A 1.5-inch 25-gauge needle will be attached to the syringe. The needle will be carefully inserted at the first trigger point and 2 mls of the mixed local anesthetic will be infiltrated. At that point, the needle will be carefully inserted into the trigger point based on the group assigned. Once needling is done for the first trigger point, the process will be repeated in exactly the same fashion for the remaining points.
Study: NCT06391697

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eOPRA Implant System for Transtibial Amputees and Magnetic Bead Tracking System
Description: The Magnetic Bead Tracking System is an investigational device that consists of pairs of magnetic beads, and a set of magnetic field sensors that measure and track the length of muscles and the speed at which they move in real-time. When the beads are implanted in muscle in the residual limb of an amputee, the muscle length signal is communicated to an investigational, robotic ankle-foot prosthesis.~The e-OPRA is an investigational implant system that lets a lower leg prosthesis attach securely to the remaining tibia bone. The e-OPRA device has been designed so that it can be implanted with an electrode set that consists of an electrical connector and electrodes to allow it to be used with both a neuro-mechanical (powered) prosthesis system, in addition to the standard prosthesis.~The operation to implant these devices will represent a modification of the surgical technique currently employed for standard below knee amputation.
Study: NCT05976191

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patients whose blood glucose is measured intravenously and from the fingertip
Description: A satisfaction survey will be conducted after these patients have previously examined their blood glucose via intravenous route, then fingertip blood glucose will be measured and a satisfaction survey will be applied.
Study: NCT05361720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT05593887

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hip reconstruction surgery.
Description: This group will undergo Hip reconstruction surgery Anterior approach overlying the iliac crest: open reduction, pelvic osteotomy and pelvic osteotomy. Lateral approach: derotation-varization osteotomy and shortening of femur, internal fixation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal femoral resection
Description: Resection of the proximal part of the femur below the level of the lesser trochanter by 2 to 3 cm and constructed a capsular flap across the acetabulum. The quadriceps muscle will be sutured around the resected end of the femur

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal femoral valgus ostetomy
Description: The patient is positioned in the lateral decubitus Position A straight incision is cantered over the greater trochanter and extends proximally. Head and neck are resected. A closing wedge, shortening, valgus-producing osteotomy of 40 to 50 degrees is marked just below the lesser trochanter and fixed by a plate
Study: NCT06099938

Intervention type: DRUG
Intervention: sufentanil, ropivacaine
Description: The study used conventional anesthetic drugs to compare the effects of the two drugs on maternal and infant blood flow

Intervention type: DRUG
Intervention: sufentanil, ropivacaine
Description: The study used conventional anesthetic drugs to compare the effects of the two drugs on maternal and infant blood flow
Study: NCT05797428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: logotherapy
Description: The logotherapy is carried out in an individual way in this study. The full-time assistant will give the experimental group 3 months of logotherapy intervention by interviewing with the participant, once every two weeks, about 1-2 hours each time, a total of 6 times of logotherapy to guide the participant to find the meaning of his life and value.The location is mainly in the hospital when the participant has to return for consultation, or at the participant's home.
Study: NCT05692388

Intervention type: OTHER
Intervention: Patient and Community Stakeholder Interviews
Description: Thirty in-depth face-to-face patient interviews, and ten in-depth structured stakeholder interviews will be conducted to explore and identify facilitators and barriers to self-care in African American adults with DKD experiencing MDA and living in the inner-city.

Intervention type: OTHER
Intervention: Cross-sectional Study Participants
Description: Three hundred African American adults with DKD experiencing MDA and living in the inner-city will be recruited to participate in a cross-sectional study. All participants will complete a one-time survey, and blood samples and blood pressure readings will be obtained to assess clinical outcomes.

Intervention type: OTHER
Intervention: Focus Groups and Intervention Mapping
Description: A subsample of patient interview/cross-sectional study participants will be invited back to participate in four focus groups (five participants/group) to review components of the intervention, give feedback on appropriateness, feasibility, acceptability, and likelihood of having an impact based on their lived experiences.
Study: NCT05832294

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment rTMS
Description: Depressed adolescents will undergo emotional processing tasks (within and outside the fMRI scanner) after one session of 1) sham rTMS (n = 15) or 2) active rTMS (n = 15). Prior to stimulation, expectancy for symptomatic benefit will be assessed with a standardized scale and a semi-structured interview conducted regarding their perception of rTMS. After the one-day randomized controlled phase, participants can then enter an open-label active rTMS treatment phase for 4 weeks. Eligible patients who decline the study and open-label treatment phase will be invited to participate in a semi-structured interview to explore their perceptions toward rTMS.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Depressed adolescents will undergo emotional processing tasks (within and outside the fMRI scanner) after one session of 1) sham rTMS (n = 15) or 2) active rTMS (n = 15). Prior to stimulation, expectancy for symptomatic benefit will be assessed with a standardized scale and a semi-structured interview conducted regarding their perception of rTMS. After the one-day randomized controlled phase, participants can then enter an open-label active rTMS treatment phase for 4 weeks. Eligible patients who decline the study and open-label treatment phase will be invited to participate in a semi-structured interview to explore their perceptions toward rTMS.
Study: NCT04431830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaning-Centered Pain Coping Skills Training
Description: The goal of this intervention is to help participants manage pain so that they can engage with what gives them a sense of meaning, purpose, and significance in life.
Study: NCT04546685

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Participants who are randomized to the Usual Care group (waitlist for cross-over to ER) will be instructed to continue with their normal pain care. They will receive only study surveys (baseline, 2 weeks, and 1 month). Upon completion of the 1-month study, UC participants will be invited to cross-over and receive ER. Post-class treatment appraisal/satisfaction data only will be collected.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowered Relief
Description: The participants will attend an online Spanish Empowered Relief class. The two hour group session is delivered by a certified instructor and includes pain neuroscience education, 3 core pain management skills, experiential exercises, completion of a personalized plan for empowered relief. Participants download a Spanish binaural relaxation audio file for daily use.
Study: NCT05086614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin Alpha1
Description: Receive thymosin-alpha 1 1.6mg with subcutaneous injection, twice a week, for 6 months after radical resection.
Study: NCT05843864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation Therapy with Standard Physical Therapy
Description: Photobiomodulation Therapy (PBMT) will be provided by a trained individual in addition to standard physical therapy. Treatment will be delivered for approximately 10-16 minutes. Participants will then be instructed to rest for 5 minutes after the treatment.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Photobiomodulation Therapy with Standard Physical Therapy
Description: Sham Photobiomodulation Therapy (PBMT) will be provided by a trained to the some location and with the same contact time and frequency as the active intervention (PBMT) in addition to standard physical therapy. Participants will then be instructed to rest for 5 minutes after the treatment.
Study: NCT04195633

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic hematopoietic stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT03743194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel 266 MG Per 20 ML Injection
Description: The local anesthetic (LA) used for the PECS II or serratus plane blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg. The LA solution can be diluted with preservative free normal saline for smaller patients to allow for appropriate volume of injection. Treatment patients will also be given liposomal bupivacaine (EXPAREL, Pacira Pharmaceuticals, Inc. San Diego, CA) in a dose of 266 mg in 20 ml can be safely combined with bupivacaine HCL at a ratio not exceeding 2:1, but cannot be combined with other local anesthetics due to the concern of rapid release of encapsulated bupivacaine and subsequent local anesthetic toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Patients randomized to standard analgesia technique will be given pain medications.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to standard analgesia technique will be given pain medications.
Study: NCT05648734

Intervention type: DRUG
Intervention: Corticosteroids alone
Description: (≥ 20 mg prednisolone or its equivalent for ≥ 10 days after hospital discharge)

Intervention type: DRUG
Intervention: Corticosteroids + Colchicine
Description: (≥ 20 mg prednisolone or its equivalent for ≥ 10 days) + Colchicine (1 mg/day for ≥ 10 days)

Intervention type: DRUG
Intervention: Corticosteroids + Pirfenidone
Description: (≥ 20 mg prednisolone or its equivalent for ≥ 10 days) + Pirfenidone (267 mg TID for ≥ 14 days)
Study: NCT05556499

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker assays
Description: Circulating bone biomarkers assays
Study: NCT04917211

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual reality mask
Description: The virtual reality mask is a mask with a screen that is put on the patient's face in the theatre before the surgery. It offers 3D scenarios of about 20 to 40 minutes on five different themes (the Zen garden, the mountain, the forest, the beach, the scuba diving) with music. The video-headset, equipped with head movement sensors, allows the 3D vision of a natural virtual world and the audio-headset emits sounds adapted to the virtual world and music therapy. The RV mask, via multi-sensorial immersion, focuses on two therapeutic targets which are pain and anxiety. It is a non-drug approach cousin to hypnosis. Its therapeutic effects are based on a distractive effect: attentive capture, an emotional effect: playfulness and positive suggestion, and a behavioral effect: the patient participates and is an actor in his care.~
Study: NCT04880200

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: POC NAT & Adherence Intervention
Description: The POC NAT test will be the SAMBA Semi-Q HIV test. The adherence intervention will be developed by study staff and tailored for delivery along with the POC NAT results.
Study: NCT05344456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Change in the device PVC algorithm to ''Off''
Description: PVC algorithm change from Atrial Pace mode to Off
Study: NCT05348655

Intervention type: OTHER
Intervention: epidemiology
Description: To review of medical records to describe diagnosis and severity of the disease

Intervention type: OTHER
Intervention: epidemiology
Description: To review of medical records to describe diagnosis and severity of the disease

Intervention type: OTHER
Intervention: epidemiology
Description: To compare pre- and per-Covid-19 epidemics in terms of numbers of admissions, and proportion of severe disease.

Intervention type: OTHER
Intervention: epidemiology
Description: To compare pre- and per-Covid-19 epidemics in terms of numbers of admissions, and proportion of severe disease.
Study: NCT05627219

Intervention type: BEHAVIORAL
Intervention: Training and Education
Description: Undergo training and education

Intervention type: OTHER
Intervention: Educational Intervention
Description: Receive educational booklet

Intervention type: PROCEDURE
Intervention: Discussion
Description: Attend discussion with peer genetic coach
Study: NCT04831281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATH-1017
Description: Daily subcutaneous injection of ATH-1017 in a pre-filled syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATH-1017
Description: Daily subcutaneous injection of ATH-1017 in a pre-filled syringe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily subcutaneous injection of Placebo in a pre-filled syringe
Study: NCT05381064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: artificial intelligence assistance system
Description: A deep learning-based bile duct scanning system that can prompt endoscopists to scan standard stations, identify bile ducts and stones in real time

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: artificial intelligence assistance system
Description: A deep learning-based bile duct scanning system that can prompt endoscopists to scan standard stations, identify bile ducts and stones in real time
Study: NCT05760443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning to BREATHE
Description: Learning 2 BREATHE (L2B) is an empirically-supported, manualized mindfulness-based group program (Broderick, 2021). Participants attend 6 sessions of approximately 1.5 hours per session. BREATHE is an acronym: Body, Reflections, Emotions, Attention, Tenderness, Habits, Empowerment; each week's lesson is centered around one of the letters (week 1 encompasses both Body and the overall theme of the sessions, Empowerment). Sample activities of L2B include psycho-education on emotion and self-regulation, body scanning, sitting meditation, non-aerobic yoga, and walking meditation, designed to promote moment-to-moment awareness of mind-body experiences. In between sessions, participants are encouraged to practice brief mindfulness skills in their daily lives and to complete the homework assignments, such as an audio-guided body scan. Participants will have access to home-practice audio-recordings and will be queried about their completion of home-practice assignments.
Study: NCT05096988

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PKU sphere liquid
Description: PKU sphere liquid will be prescribed by the study dietitian based on the patient's individual requirements.
Study: NCT06411795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Given via epidural and injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Given via epidural and injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Given via epidural

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopamidol
Description: Given via epidural

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: Given injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Analgesia
Description: Undergo thoracic epidural placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo ultrasound

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray
Study: NCT06538883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedation with Ciprofol
Description: During the drug administration period, ciprofol were IV infused at loading doses of 0.1 mg/kg, respectively, over 4 minutes ± 30 seconds depending on the physical condition of each patient. Ciprofol were then immediately administered at an initial maintenance dose of 0.3 mg/kg/hr, with a target sedation depth of RASS +1 to -2, based on the Pain, Agitation/sedation, Delirium, Immobility (rehabilitation/mobilization), and Sleep (disruption) guideline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sedation with Propofol
Description: During the drug administration period, propofol were IV infused at loading doses of 0.5 mg/kg, respectively, over 4 minutes ± 30 seconds depending on the physical condition of each patient. Propofol were then immediately administered at an initial maintenance dose of 1.5 mg/kg/hr, with a target sedation depth of RASS +1 to -2, based on the Pain, Agitation/sedation, Delirium, Immobility (rehabilitation/mobilization), and Sleep (disruption) guideline.
Study: NCT05350826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambulatory medical assistance
Description: Ambulatory medical assistance is a patient-empowerment program and consists to programmed phone calls (bi-monthly for the first 6 months then monthly for the following 6 months) delivered by an oncology nurse, in link with the hematologist.
Study: NCT05811403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate (EGCG)
Description: Epigallocatechin gallate (EGCG) is a white powder that can be obtained from tea leaves. It accounts for 50-60 % of catechin content of tea polyphenols with a wide range of biological activities including antioxidant, antimicrobial, anti-inflammatory, immune regulatory, anti-tumour effects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate (EGCG)
Description: Epigallocatechin gallate (EGCG) is a white powder that can be obtained from tea leaves. It accounts for 50-60 % of catechin content of tea polyphenols with a wide range of biological activities including antioxidant, antimicrobial, anti-inflammatory, immune regulatory, anti-tumour effects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hypochlorite (NaOCl)
Description: Sodium hypochlorite (NaOCl) is an excellent non-specific proteolytic and antimicrobial agent that provides disinfection of the dentin-pulp interface.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite (NaOCl)
Description: Sodium hypochlorite (NaOCl) is an excellent non-specific proteolytic and antimicrobial agent that provides disinfection of the dentin-pulp interface.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Description: Mineral trioxide aggregate (MTA) is the material of choice for pulp capping in vital pulp therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mineral trioxide aggregate (MTA)
Description: Mineral trioxide aggregate (MTA) is the material of choice for pulp capping in vital pulp therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Premixed bioceramic putty
Description: Bioceramic putty is a premixed, ready-to-use calcium silicate-based material which can be used as a pulp capping material.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Premixed bioceramic putty
Description: Bioceramic putty is a premixed, ready-to-use calcium silicate-based material which can be used as a pulp capping material.
Study: NCT04195633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV or PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV